

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Proteomics International Laboratories Ltd
ABN	78 169 979 971

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Richard Lipscombe
Date of last notice	23 March 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Richard John Lipscombe <The Luk Trust A/C> Dr Lipscombe is the trustee and a beneficiary of the trust. Bjouxz Pty Ltd <The Loz Superannuation Fund> Dr Lipscombe is beneficiary of the superannuation fund and sole director and shareholder of the trustee.
Date of change	6 April 2018.
No. of securities held prior to change	<i>Direct</i> 9,192,192 fully paid ordinary shares ("Shares") 882,423 options exercisable at \$0.20 each on or before 31 March 2018 ("Options") 75 performance rights <i>Indirect</i> 7,061,589 Shares 2,127,898 Options

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Class	(a) Options. (b) Shares. (c) Shares. (d) Options.
Number acquired	(a) Not applicable. (b) 1,275,000 Shares. (c) 1,482,423 Shares. (d) Not applicable.
Number disposed	(a) 2,757,423 Options. (b) Not applicable. (c) Not applicable. (d) 252,898 Options.
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	(a) Nil. (b) \$255,000. (c) Loan amounts of \$296,484.60 advanced by Dr Lipscombe were offset against application monies for the conversion of PIQO Options. (d) Nil.
No. of securities held after change	<i>Direct</i> 10,074,615 Shares 75 performance rights <i>Indirect</i> 8,936,589 Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	(a) Exercise of Options. (b) Issue of Shares on exercise of Options. (c) Issue of Shares on exercise of Options. (d) Options lapsed on 31 March 2018.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable.
Nature of interest	

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No. Although the exercise of options took place in a Closed Period, the Company's Trading Policy does not apply to the exercise of options during a Closed Period.
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.